• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations

Opinion
Video

Panelists discuss how amyloid-targeting therapies for Alzheimer disease represent a breakthrough drug class that works by binding to and removing beta-amyloid plaques through various mechanisms, demonstrating modest cognitive decline reduction in clinical trials while presenting safety considerations including amyloid-related imaging abnormalities (ARIA), infusion reactions, and the need for careful patient selection and monitoring protocols.

Related Videos
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
5 experts are featured in this series
4 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.